{'fraction_non_alphanumeric': 0.06092124814264487, 'fraction_numerical': 0.041604754829123326, 'mean_word_length': 4.856521739130435, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of Topical Flurbiprofen on Trabeculectomy

Purpose and MethodsThe effect of topical flurbiprofen, in addition to our ususal topical postoperative medications (prednisolone 1%, phenylephrine 2.5%, atropine 1%, and gentamycin 0.3%), on the outcome of trabeculectomy was assessed in a prospective, placebo-controlled, randomized study of 49 eyes. Mean postoperative follow-up was 42 weeks (range, 4–52 weeks). ResultsIntraocular pressure was higher in the flurbiprofen (Ocufen, Allergan Pharmaceuticals) treated eyes than in the placebo control eyes, but they are not significantly different (15.7 ± 1.1 vs. 12.8 ± 1.2 mm Hg, p = 0.20, mean ± SE). Similar results were observed for visual acuity using the Log-MAR scale (-0.45 ± 0.06 vs. −0.52 ± 0.07, p = 0.42, mean ± SE). For both visual acuity and intraocular pressure, the flubiprofen effect did not change significantly with the follow-up period. There were more encapsulated filtering blebs in flurbiprofen-treated eyes (11/24 eyes, 46%) than in eyes treated with the artificial tear placebo (5/25 eyes, 20%), though the difference was only marginally significant (p = 0.058). No other differences in adverse effects were noted between the two groups. ConclusionThese results suggest that there is no benefit of using postoperative flurbiprofen following initial trabeculectomy surgery.